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Abstract:  Continuous glucose monitoring (CGM) devices have the potential to reduce nurse workload in 
the ICU while improving glycaemic control (GC). However, larger point accuracy errors that are inherent 
in these devices can lead to adverse consequences for GC performance and safety. There is a need to 
characterize this error, caused by drift and sensor noise, to evaluate the impact it would have on GC when 
using CGM devices instead of intermittent blood glucose (BG) measurements. This paper presents an auto-
regressive model to model the drift and sensor noise, which can then be used to simulate further CGM 
sensor traces. Validation by comparison between the original clinical data and the simulated sensor data is 
used to provide qualitative and quantitative assurance of model accuracy. The auto-regressive model and 
simulated CGM sensor traces are found to represent the Glysure CGM sensor well, and capture all 
necessary sensor behaviors. 




Critically ill patients commonly experience insulin resistance 
and stress induced hyperglycaemia (Capes et al., 2000; 
Krinsley, 2003; van den Berghe et al., 2001), which has been 
associated with increased morbidity and mortality (Capes et 
al., 2000; Krinsley, 2003; Umpierrez et al., 2002). Some 
studies have shown glycaemic control (GC) can reduce 
hyperglycaemia and improve outcomes (Chase et al., 2008b; 
Krinsley, 2004; van den Berghe et al., 2001). However, other 
studies have failed to replicate these results (Brunkhorst et al., 
2008; Finfer et al., 2009; Hirasawa et al., 2009), with some 
even reporting an increase in mortality (Finfer et al., 2009). 
A potential confounding factor is the increased hypoglycaemia 
observed across almost all these studies (Wiener et al., 2008). 
Hypoglycaemia is associated with increased mortality 
(Bagshaw et al., 2009; Egi et al., 2010; Finfer et al., 2012), 
with one study showing increased mortality after a single event 
(Bagshaw et al., 2009). Thus, it is important that GC protocols 
are able to treat hyperglycaemia safely and effectively to 
achieve the potential outcome benefits. 
Hypoglycaemia often occurs where infrequent blood glucose 
(BG) measurements combine with changes in patient response 
to care (Chase et al., 2008a; Chase et al., 2006). Continuous 
glucose monitoring (CGM) devices could help provide safety 
from hypoglycaemia, reduce workload by increasing 
automation, and improve GC. The increased temporal 
resolution CGM devices provide can monitor real-time BG 
trends, allowing more rapid response to changes to avoid 
hypoglycaemia. 
CGM devices can also reduce GC related nursing workload, 
providing more data with lower blood sampling requirements 
(Boom et al., 2014; Holzinger et al., 2010; Signal et al., 2010). 
However, the increased temporal measurement resolution 
CGM devices provide is still somewhat outweighed by the 
larger errors in these devices due to sensor drift, bias, and noise 
(Facchinetti et al., 2014; Kuure-Kinsey et al., 2006; Reifman 
et al., 2007; Signal et al., 2010; Zimmermann et al., 2012). 
There is thus a need to model and account for sensor error 
when integrating CGM sensors in GC.  
The Glysure (GlySure Limited, UK) sensor is a CGM device 
that measures venous BG via an intravenous line. This paper 
presents an auto-regressive (AR) method and model 
characterising the Glysure CGM sensor. This model is 
compared to clinical data to assess validity, and the overall 
modelling method is generalisable. 
2. METHOD 
2.1 Sensor Modelling 
2.1.1 Clinical Data 
Data from a pilot trial of the Glysure CGM device on 33 
cardiac intensive care patients for an average of 37.6 hours is 
used. It was an observational trial and CGM measures were 
not used for GC. The sensor provides a new reading 4 times 
per minute. Intermittent BG measures are used to calibrate the 
sensor approximately every 8 hours. Intermittent BG measures 
not used to calibrate the sensor were taken approximately 
every 2.5 hours. Data from 2 patients was discarded due to 
sensor failure. 
2.1.2 Sensor Characterisation 
Sensor characterisation two auto-regressive (AR) models to 
capture drift and higher frequency sensor fluctuations. Drift is 
 
 
     
 
characterised as the percentage difference between sensor and 
reference measurements. It is assessed half-hourly using BG 
interpolated from the calibration and reference measurements. 
Half hourly interpolation of intermittent BG measures is 
defined: 
𝐵𝐺𝐼𝑀/30 𝑚𝑖𝑛 = 𝑖𝑛𝑡𝑒𝑟𝑝(𝐵𝐺𝐼𝑀)|𝑡=0:30:𝑡𝑒𝑛𝑑  (1) 
Half hourly sampling of the CGM sensor trace is defined: 
𝐵𝐺𝑆𝐺/30 𝑚𝑖𝑛 = 𝑠𝑎𝑚𝑝𝑙𝑒(𝐵𝐺𝑠𝑒𝑛𝑠𝑜𝑟)|𝑡=0:30:𝑡𝑒𝑛𝑑 (2) 




   (3) 
A lag-2 AR model was the used to characterise drift, defined: 
𝐷𝑟𝑖𝑓𝑡𝑛+1 = 𝛼𝑑 + 𝛽𝑑 ∗ 𝐷𝑟𝑖𝑓𝑡𝑛−1 + 𝛾𝑑 ∗ 𝐷𝑟𝑖𝑓𝑡𝑛 + 𝜉𝑑
      (4) 
Model parameters αd, βd and γd are found using linear least 
squares from half hourly [Driftn+1, Driftn, and Driftn-1] data 
points derived from the entire clinical data cohort and 
Equations 1-3, assuming ξd = 0. The half hourly interpolation 
interval was chosen to match observed time frames for 
fluctuations in BG across the sensor clinical data. 
Having identified a best fit αd, βd and γd, a noise term was 
calculated by re-arranging Equation 4 and solving for the 
residuals, ξd.  Outlier drifts from Equation 3 of more than 
±25%, the threshold capturing over 99.3% of the data, were 
discarded to maintain sufficient data density for probability 
modelling. The results are used to create a drift noise model by 
smoothing a continuous distribution function across ξd residual 
results using Equation 4 and all the data. 
Sensor noise fluctuations is assessed every 0.25 minutes and 
sampled from the interpolated BG and CGM device 
measurements such that: 
𝐵𝐺𝑏𝑎𝑠𝑒/0.25 𝑚𝑖𝑛𝑢𝑡𝑒𝑠 = 𝑖𝑛𝑡𝑒𝑟𝑝(𝐵𝐺𝑆𝐺/30𝑚𝑖𝑛)|𝑡=0:0.25:𝑡𝑒𝑛𝑑
      (5) 
The fractional difference between these linearly interpolated 





Another lag-2 AR model is used to characterise these high 
frequency sensor fluctuations such that: 
𝑆𝑒𝑛𝑠𝑜𝑟𝐹𝑙𝑢𝑥𝑛+1 = 𝛼𝑠𝑓 + 𝛽𝑠𝑓 ∗ 𝑆𝑒𝑛𝑠𝑜𝑟𝐹𝑙𝑢𝑥𝑛−1 +
𝛾𝑠𝑓 ∗ 𝑆𝑒𝑛𝑠𝑜𝑟𝐹𝑙𝑢𝑥𝑛 + 𝜉𝑠𝑓   (7) 
The model parameters αsf, βsf and γsf are found using the entire 
data cohort and linear least squares from 0.25 minute 
[SensorFluxn+1, SensorFluxn, and SensorFluxn-1] data points 
derived from clinical data and Equation 6, assuming ξsf = 0. 
 
After identifying a linear best fit for αsf, βsf and γsf across the 
entire data cohort, the sensor fluctuation noise term was 
calculated by re-arranging Equation 7 and solving for the 
residuals, ξsf.  Outlier fluctuations of more than ±1%, which 
includes over 99.9% of the data, were discarded. These results 
are used to create a sensor fluctuation noise model, similar to 
the drift noise model, by smoothing a continuous distribution 
function across the data range of ξsf. 
An example of the modelling process is shown using data from 
Patient 2 in Figure 1. Figure 1a shows the sensor clinical data 
for Patient 2 over the first 16 hours. Figures 1b and 1c show 
characterisation of the AR drift model using Equations 3 and 
4, where Figure 1c shows the plane of best fit for model 
parameters αd, βd and γd, and the drift noise term definition (ξd). 
Figures 1d-1f show characterisation of the sensor fluctuation 
model using Equation 6 and 7, with planes of best fit for model 
parameters αsf, βsf and γsf and the sensor fluctuations noise term 
definition (ξsf). 
2.2 Sensor Simulation 
Sensor simulation is where a sensor trace is simulated from 
intermittent BG measures. Intermittent BG measures are used 
as a base to simulate the CGM sensor. They are interpolated 
half hourly, and drift applied using Equation 4. The resulting 
BG with drift is: 
𝐵𝐺𝑏𝑎𝑠𝑒(𝑡=0:30:𝑡𝑒𝑛𝑑) = 𝐵𝐺𝐼𝑀/30 𝑚𝑖𝑛𝑢𝑡𝑒𝑠(1 + 𝐷𝑟𝑖𝑓𝑡)
      (8) 
Where Drift is calculated using Equation 4, with ξd drawn 
randomly from the cohort probability distribution generated 
from the clinical data. At t = 0, and at any calibration BG, the 
condition [Driftn, Driftn-1] = [0.0, 0.0] is used to recalibrate the 
CGM sensor to match the simulated intermittent BG 
measurement, similar to the actual sensor process. 
The simulated sensor output is then defined: 
𝐵𝐺𝑛𝑒𝑤_𝑠𝑒𝑛𝑠𝑜𝑟(𝑡=0:0.25:𝑡𝑒𝑛𝑑) = 𝐵𝐺𝑏𝑎𝑠𝑒/0.25 𝑚𝑖𝑛𝑢𝑡𝑒𝑠(1 +
𝑆𝑒𝑛𝑠𝑜𝑟𝐹𝑙𝑢𝑥)     (9) 
Where SensorFlux is calculated according to Equation 7, with 
ξsf drawn randomly from the cohort probability distribution 
generated from clinical data. BGbase/0.25 minutes is now: 
𝐵𝐺𝑏𝑎𝑠𝑒/0.25 𝑚𝑖𝑛𝑢𝑡𝑒𝑠 = 𝑖𝑛𝑡𝑒𝑟𝑝(𝐵𝐺𝑏𝑎𝑠𝑒)|𝑡=0:0.25:𝑡𝑒𝑛𝑑
      (10) 
Once again, at t = 0 and any calibration BG, the condition 
[SensorFluxn, SensorFluxn-1] = [0.0, 0.0] is used to recalibrate 
the CGM sensor. An additional limit of a maximum drift of 
40% was applied to the drift AR model matching extremes 
seen in the clinical sensor data. 
 
 
     
 
Setting [Driftn, Driftn-1] = [0.0, 0.0] and [SensorFluxn, 
SensorFluxn-1] = [0.0, 0.0] effectively applies a point to point 
recalibration allowing the sensor trace to go through a 
recalibration point. Divergence from the interpolated BG is 
then initiated by the ξd and ξsf terms. Figure 2 outlines the steps 
that occur during the simulation, with a sensor trace and virtual 
patient forward simulated for the first 4 hours in Figure 2(a). 
2.3 Sensor Model Validation 
Sensor traces are simulated using intermittent BG from the 
clinical data cohort from which the model was built. To test 
consistency between the model and the sensor clinical data, 
several sensor simulations were overlaid with the clinical data 
and compared. If the clinical sensor traces were difficult to 
visually distinguish from simulation, then the model was 
qualitatively accepted as broadly capturing key behaviour.  
To quantitatively validate the model, a simulation was run to 
generate a single sensor trace from the sensor model for each 
patient to compare to the sensor clinical data. The mean 
absolute relative difference (MARD) distributions for the 
simulations and the sensor clinical data were compared, and a 
Clarke Error Grid (CEG) plot and Bland-Altman plot 
constructed. A CEG plot was used to further validate the 
sensor model against the clinical data. A Bland-Altman plot 
enabled analysis of any differences in bias behaviour between 
actual and modelled sensor traces. 
3. RESULTS AND DISCUSSION 
3.1 Sensor Characterisation 
Table 1 gives sensor model parameters identified from the 
cohort data, and Figure 3 shows the noise term models for drift 
and sensor fluctuations, ξd and ξsf. Figure 4 shows an example 
patient with the real sensor trace plotted alongside simulated 
traces. Sensor behaviour is visually consistent between 
simulated and real sensor traces, with drift and sensor 
fluctuations of approximately the same magnitude across all 
traces. 
Figure 5 shows the MARD distribution over the total clinical 
and simulated clinical data. The simulated data distribution is 
slightly tighter than the clinical data at the extremes. However, 
it is still very similar, reflecting the non-Gaussian distribution 
of MARD at these extremes, compared to the Gaussian noise 
distribution used. 
Table 1: Auto-regressive (AR) model parameters for drift and sensor fluctuations 
AR 
Pass 
Key Characteristic 𝜶 𝜷 𝜸 𝝃 median 𝝃 max (absolute) R2 
1 Drift -0.00096 -0.05877 0.9393 -0.0028 0.2439 0.78 
2 Sensor Fluctuations -4.4e-6 -0.224 1.215 -5.415e-06 0.01 0.99 
 
 
a) Clinical data plotted for Patient 2. 
 
b) Patient 2 with BG resampled every half 
hour. Red arrows show how Drift was 
characterised (Drift = (BGSG/30min-
BGIM/30min)/BGIM/30min) 
 
c) Driftn+1 plotted against current (Driftn) and 
previous (Driftn-1) for all patients. The plane of 
best fit is shown in black, with a red arrow 
showing how ξd is sampled. 
 
d) Patient 2 with BG resampled every 
minute. Red arrows show how the 
sensor fluctuation was characterised. 
 
e) SensorFluxn+1 plotted against SensorFluxn 
and SensorFluxn-1 for all patients. The plane of 
best fit is shown. 
 
f) SensorFluxn+1 plotted against SensorFluxn 
and SensorFluxn-1 with a red arrow showing how 
the ξsf is sampled for the fluctuations. 
Figure 1. Steps of the sensor characterisation process, showing how the drift and sensor fluctuations were characterised. 
 
 
     
 
 
(a) Noise model for drift, ξd. 
 
(b) Noise model for sensor 
fluctuations, ξsf. 
Figure 3: Random noise distributions for auto-regressive drift 
and sensor fluctuations (fraction) 
The Clarke Error Grid (CEG) in Figure 6 shows the model 
behaves in a consistent manner to the clinical data. At lower 
BG, where there are fewer data points, error is slightly, though 
not significantly, overestimated, which is conservative in 
simulating sensor use in GC. In Figure 7, the Bland-Altman 
plot shows no significant bias across the observed BG range, 
and the plotted lines of ±2σ for the clinical and simulated data 
show the strong similarity between the model outputs and 
clinical data. Overall, the model is considered to represent the 
sensor well. 
 
Figure 4. Sensor clinical data with two sensor traces generated 
from the model. 
Worth noting is that the sensor clinical data had almost no BG 
<5 mmol/L. Underlying sensor model assumptions apply 
constant sensor behaviour across the full BG range resulting in 
similar proportional BG error at high and low BG. This 
assumption is used for lack of other data at this time. In this 
case, at lower BG, this choice translates to a consistent 
percentage error, resulting in lower absolute BG errors.  
 
a) An example patient. Intermittent glucometer BG are 
interpolated between measurements. 
 
b) AR drift is applied to the interpolated BG at half hour 
intervals. 
 
c) AR sensor fluctuations are added to the interpolated AR 
drift. 
 
d) Comparison of intermittent BG and final sensor 
simulation. 
Figure 2. Sensor simulation steps during a virtual trial. 
 
 
     
 
 
Figure 5. MARD plot of the sensor clinical data vs. the simulated 
data. 
 
Figure 6. Clarke Error Grid plot of the sensor clinical data and 
the clinical simulated data, both resampled half hourly. 
 
Figure 7. Bland-Altman plot of sensor clinical data and simulated 
clinical data. 
 
Overall, a sensor model was characterised from clinical data 
and was found to simulate sensor behaviour well. The MARD 
distribution and CEG plots for the simulated sensor and the 
clinical data are very similar. Equally, simulated sensor traces 
were difficult to visually distinguish from clinical data. 
3.2 Limitations 
One of the limitations of this study was that in the making of 
the sensor model, the clinical data used to construct the model 
had a very low number of BG measurements less than 5 
mmol/L. This limitation makes it hard to predict sensor 
behaviour at this lower BG region, and it was assumed that the 
sensor behaviour was constant for the range of BG measured. 
Future research would need to target this region of BG to 
develop more a reliable sensor model at lower BG. 
Another limitation arises from the sensor clinical data, in 
which there were only 1277 hours of recorded data and the 
median recording period was 37.6 hours. More data needs to 
be gathered from patients that stay for longer than 37.6 hours 
to more accurately model long term sensor measurements in 
critical care patients.  
Finally, the analysis was limited by the amount of patient data 
from the clinical trial. A larger clinical cohort would have 
allowed more in-depth analysis through cross-validation. 
However, the results from the MARD, CEG plot and Bland-
Altman plot indicate that there was enough data to generate a 
satisfactory model. 
4.  CONCLUSIONS 
A CGM sensor model was developed and was able to 
successfully model the Glysure CGM device. The drift and 
sensor fluctuations are characterised from clinical data, and 
then used to simulate the sensor traces on top of the clinical 
data. The clinical data and simulated data were quantitatively 
validated through the MARD, CEG plots and Bland-Altman 
plots, and thus showed that the simulated sensor represented 
the Glysure CGM sensor well. The overall approach is fully 
generalisable to similar sensors. 
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